Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Mrk save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
health treatment for canada advanced keytruda
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
fda group treatment hypertension
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Published: 2023-12-11 (Crawled : 14:30) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 1.06%
H: 0.59%
C: -0.46%
MRNA S | $102.68 0.67% 640K
|
Health Technology
|
| O: -0.47%
H: 3.28%
C: 2.58%
rna-4157 keytruda lung merck cancer cell treatment study
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.45%
H: 0.51%
C: -1.41%
keytruda chmp merck positive cancer treatment plus gemcitabine
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-01 (Crawled : 11:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.83%
H: 0.66%
C: -0.68%
keytruda fda cancer treatment plus gemcitabine
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Published: 2023-10-25 (Crawled : 12:30) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.31%
H: 1.22%
C: 0.27%
renal cell treatment lenvima plus keytruda
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Published: 2023-10-16 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.06%
keytruda lung cancer cell treatment risk
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2023-09-20 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.79%
H: 0.18%
C: -0.83%
keytruda fda review cancer treatment application grants plus
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 1.28%
H: 0.0%
C: 0.0%
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: -0.31%
H: 0.96%
C: -1.35%
lynparza japan approved cancer treatment plus
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Published: 2023-07-26 (Crawled : 11:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: -0.68%
H: 1.13%
C: 0.32%
MRNA S | $102.68 0.67% 640K
|
Health Technology
|
| O: 0.0%
H: 0.07%
C: -1.0%
rna-4157 keytruda melanoma merck treatment study
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.25%
H: 1.73%
C: 1.53%
keytruda chmp merck positive treatment plus
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2023-06-16 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.09%
H: 0.87%
C: -0.16%
keytruda treatment plus
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Published: 2023-06-08 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: -0.28%
H: 2.55%
C: 1.86%
keytruda fda cancer treatment application plus
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 0.0%
H: 0.51%
C: -0.66%
merck asco pipeline treatment research meeting
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2023-04-13 (Crawled : 11:00) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: 1.07%
H: 0.74%
C: 0.53%
keytruda fda treatment application plus
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Published: 2023-03-10 (Crawled : 12:20) - biospace.com/
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: -0.15%
H: 3.05%
C: 0.23%
keytruda treatment plus
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2023-03-02 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 1.68%
H: 0.0%
C: 0.0%
MRK | $125.31 0.06% 2.3M
|
Health Technology
|
| O: -0.02%
H: 0.7%
C: 0.36%
lynparza treatment review update cancer
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.